Following people with ANCA-associated vasculitis in Hunan, China
Follows people with ANCA-associated vasculitis over time, without giving any treatment.
Plain-language title generated from the registry record
Registry title: Multicenter Cohort Study of AAV in Hunan of China
Key facts
- Where
- Changsha, ChinaSee the site
Where in China
- Xiangya HospitalChangsha, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Xiangya Hospital of Central South University
- Trial code
- NCT05315141
- Record updated
- 7 April 2022
- Original description
This study aimed to explore the incidence of Anti-neutrophil cytoplasmic antibody (ANCA）-associated vasculitis (AAV) progression and its association with adverse consequences. It will enroll approximately 500 AAV patients in Hunan province of China and follow-up for at least 5 years. Demographic characteristics, clinical and laboratory data will be collected at baseline and every follow-up. The principal clinical outcomes of the study consist of end stage renal disease (ESRD) and death.Read full original descriptionShow less
Multicenter Cohort Study of ANCA-associated Small Vasculitis in Hunan Province of China
This study aimed to explore the incidence of Anti-neutrophil cytoplasmic antibody (ANCA）-associated vasculitis (AAV) progression and its association with adverse consequences. It will enroll approximately 500 AAV patients in Hunan province of China and follow-up for at least 5 years. Demographic characteristics, clinical and laboratory data will be collected at baseline and every follow-up. The principal clinical outcomes of the study consist of end stage renal disease (ESRD) and death.
Inclusion: Fulfill 2012 criteria of ANCA associated vasculitis and agree to sign informed consent.
Exclusion: Do not agree to sign informed consent.